The company said its Phase II ZUPREME-1 trial in overweight or obese individuals without type 2 diabetes showed weight loss of 10.7% at week 42 on an efficacy estimand basis for t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results